Common Virus News Today

The FDA approved Arexvy, the world's first vaccine for respiratory syncytial virus (RSV), on Wednesday. Manufactured by GlaxoSmithKline Pharmaceuticals, the RSV vaccine is approved for use in people ages 60 and older.

Pfizer announced that its respiratory syncytial virus (RSV) vaccine showed an efficacy of 82 percent against hospitalization in infants under 90 days old, and 69 percent among those younger than six months.

Not much is known about CMV, which is a complete surprise given that it is called a common virus by some. Pregnant women need to be aware of this virus, though, as it is the most common infectious cause of disability in newborn babies.